Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE recommends infliximab and adalimumab for Crohn's disease treatment

  • 1 Comment

In final draft guidance published today (4 March) NICE has recommended infliximab and adalimumab as treatment options for people with severe, active Crohn’s disease whose condition has not responded to conventional therapy, or who are intolerant of or have contraindications to conventional therapy.

The draft guidance from NICE recommends infliximab and adalimumab as treatment options for adults with severe, active Crohn’s disease that has not responded to conventional treatment, or who are intolerant of or have contraindications to conventional therapy.

Treatment should normally be started with the less expensive drug (taking into account drug administration costs, required dose and product price per dose).

Infliximab is also recommended for adults with active, fistulising Crohn’s disease, and for children and young people aged 6-17 years old with severe, active Crohn’s disease.

Crohn’s disease is a chronic inflammatory condition of unknown cause affecting the gastrointestinal tract (gut). It is estimated that around 60,000 people in the UK have the disease, with approximately 3,000 (5%) having the most severe forms of the condition. The disease causes parts of the gastrointestinal tract to become inflamed, causing diarrhoea, pain in the abdomen, weight loss and tiredness.

  • 1 Comment

Readers' comments (1)

  • Almost certainly, Crohn's is an auto immune disorder, linked to chromosomal abnormalities, triggered by a physiological change or event or something of a similar nature. Research has pointed to Smoking as one potential trigger. It is only with the advent of immunosuppresents that Chron's has become fairly controllable. Without doubt, patient's that would have previously required surgery of one sort or another, are now having their disease progress severly curtailed with much longer periods of remission for the vast majority.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs